# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Emergent reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of losses of 83 cents by 171....
ALLR: 151% | Allarity Therapeutics shares are trading higher after the company announced that Stenoparib shows a clear clinical...